Zami Aberman
2009
In 2009, Zami Aberman earned a total compensation of $580.3K as Chief Executive Officer at Pluristem Therapeutics, a 24% decrease compared to previous year.
Compensation breakdown
| Salary | $247,918 |
|---|---|
| Stock Awards | $332,380 |
| Total | $580,298 |
Aberman received $332.4K in stock awards, accounting for 57% of the total pay in 2009.
Aberman also received $247.9K in salary.
Rankings
In 2009, Zami Aberman's compensation ranked 6,344th out of 9,885 executives tracked by ExecPay. In other words, Aberman earned more than 35.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,344 out of 9,885 | 36th |
Division Manufacturing | 2,315 out of 3,690 | 37th |
Major group Chemicals And Allied Products | 501 out of 866 | 42nd |
Industry group Drugs | 337 out of 638 | 47th |
Industry Biological Products, Except Diagnostic Substances | 67 out of 133 | 50th |
Source: SEC filing on November 23, 2009.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2009.
2009
Yaky Yanay
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019